| abstract |
3-oxygermylpropionic acid ([(O1/2)3GeCH2CH2COOH]n ("3-OGP") has been known to have pharmacological activity, preferably with a stabiliser. It is now found that 3-OGP is effective in treating cold syndrome, e.g. at a dose of 10 mg to 150 mg/kg body weight in humans, or a daily adult dose of 150 mg; e.g. in tablets. Preferably the 3-OGP is used with an activating carrier, e.g. hydroxypropyl cellulose, in an amount of 0.005 to 50 % by weight per 0.005 to 20 % by weight of the OGP. |